Turn on, tune in: New York biotech scores $15M+ in chemogenetics bet
Typically, once a biological target has been identified, scientists work on developing molecules focused on that target. But in an emerging field called chemogenetics, researchers start with a small molecule and then design a target for it.
Banking on its chemogenetics technology to address CNS disorders, New York-based Redpin Therapeutics has secured a $15.5 million injection, as it shepherds its two preclinical programs — for chronic pain and refractory epilepsy — into the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.